X

Drug Profile

Research programme: hepatitis C and tetanus therapy - Abiogen

Alternative Names: AT1 - Abiogen; ATE - Abiogen

Latest Information Update: 18 May 2006

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Abiogen Pharma
Class Monoclonal antibodies
Mechanism of Action Undefined mechanism

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No

Highest Development Phases

Discontinued Hepatitis C; Tetanus

Most Recent Events

18 May 2006 This programme is still in active development
14 Nov 2003 Preclinical trials in Hepatitis C in Italy (unspecified route)
14 Nov 2003 Preclinical trials in Tetanus in Italy (unspecified route)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com